References
- Pui C H, Howard S C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008; 9: 257–268
- Bomgaars L, Geyer J R, Franklin J, Dahl G, Park J, Winick N J, et al. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 2004; 22: 3916–3921
- Chamberlain M C, Kormanik P, Howell S B, Kim S. Pharmacokinetics of intralumbar DTC-101 for the treatment of leptomeningeal metastases. Arch Neurol 1995; 52: 912–917
- Kim S, Chatelut E, Kim J C, Howell S B, Cates C, Kormanik P A, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol 1993; 11: 2186–2193
- Glantz M J, LaFollette S, Jaeckle K A, Shapiro W, Swinnen L, Rozental J R, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999; 17: 3110–3116
- Glantz M J, Jaeckle K A, Chamberlain M C, Phuphanich S, Recht L, Swinnen L J, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999; 5: 3394–3402
- Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007; 109: 3214–3218
- McClune B, Buadi F K, Aslam N, Przepiorka D. Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. Leuk Lymphoma 2007; 48: 1849–1851
- Pui C H. Toward optimal use of intrathecal liposomal cytarabine. Leuk Lymphoma 2007; 48: 1672–1673
- Parasole R, Menna G, Marra N, Petruzziello F, Locatelli F, Mangione A, et al. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions. Leukemia Lymphoma 2008; 49: 1552–1558
- Benesch M, Sovinz P, Krammer B, Lackner H, Mann G, Schwinger W, et al. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol 2007; 29: 222–226
- Jaeckle K A, Phuphanich S, Bent M J, Aiken R, Batchelor T, Campbell T, et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001; 84: 157–163
- Sancho J M, Ribera J M, Romero M J, Martin-Reina V, Giraldo P, Ruiz E. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases. Haematologica 2006; 91, ECR02
- Sancho J M, Deben G, Parker A, Pinana J L, Bolam S, Sanchez-Garcia E, et al. Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis. Int J Hematol 2007; 86: 33–36